Oct 31, 2022 7:00 am EDT Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma
Oct 27, 2022 7:00 am EDT Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program
Oct 25, 2022 7:00 am EDT New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus over the Standard of Care Alone
Oct 24, 2022 7:00 am EDT Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors
Oct 20, 2022 5:00 pm EDT New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure
Oct 19, 2022 7:00 am EDT Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2
Oct 13, 2022 7:00 am EDT Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management
Oct 11, 2022 7:00 am EDT Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting
Oct 10, 2022 7:00 am EDT Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
Sep 23, 2022 7:00 am EDT Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous Melanoma
